Outcomes of a phase 2 trial for the inhaled JAK inhibitor, nezulcitinib, in hospitalized patients with acute lung injury due to severe COVID-19
R. Saggar (South San Francisco, United States), D. Singh ( Wythenshawe, United Kingdom), E. Moran (South San Francisco, United States), D. Lombardi (South San Francisco, United States), T. Nguyen (South San Francisco, United States), D. Bourdet (South San Francisco, United States), N. Pfeifer (South San Francisco, United States), J. Woo (South San Francisco, United States), J. Belperio (Los Angeles, United States)
Source: International Congress 2022 – COVID treatments
Session: COVID treatments
Session type: Thematic Poster
Number: 2599
 
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
R. Saggar (South San Francisco, United States), D. Singh ( Wythenshawe, United Kingdom), E. Moran (South San Francisco, United States), D. Lombardi (South San Francisco, United States), T. Nguyen (South San Francisco, United States), D. Bourdet (South San Francisco, United States), N. Pfeifer (South San Francisco, United States), J. Woo (South San Francisco, United States), J. Belperio (Los Angeles, United States). Outcomes of a phase 2 trial for the inhaled JAK inhibitor, nezulcitinib, in hospitalized patients with acute lung injury due to severe COVID-19. 2599
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|